Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.49 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 3/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.40 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990288 | 0.95 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9ATGFBR1TGFBR2 | |
| SCHEMBL4839190 | 0.84 | NPC1 (0.59) | SMN1; SMN2NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL991856 | 0.80 | NPC1 (0.65) | SMN1; SMN2NPC1RAB9ATGFBR1ALDH1A1 | |
| SCHEMBL9436258 | 0.78 | TGFBR1 (0.69) | SMN1; SMN2NPC1RAB9ATGFBR1TGFBR2 | |
| SCHEMBL15733342 | 0.78 | NPC1 (0.63) | SMN1; SMN2NPC1RAB9ATGFBR1ALDH1A1 | |
| SCHEMBL9700043 | 0.77 | TGFBR1 (0.60) | SMN1; SMN2TGFBR1TGFBR2HPGDKDM4E | |
| SCHEMBL15823276 | 0.77 | CSNK1D (0.42) | SMN1; SMN2NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL9293426 | 0.74 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ATGFBR1TGFBR2 | |
| SCHEMBL7343693 | 0.72 | TGFBR1 (0.65) | SMN1; SMN2TGFBR1TGFBR2HPGDKDM4E | |
| SCHEMBL12781729 | 0.72 | SMN1; SMN2 (0.41) | SMN1; SMN2NPC1RAB9ATGFBR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935271-B1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-2935271-B1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556179-B2 | Substituted imidazoles as casein kinase 1 D/E inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-03 | — | — | US | disclosed |
| EP-2935271-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 / INHIBITORS | Bristol-Myers Squibb Company (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014100533-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014100533-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344481-A1 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS | CSNK1E, CSNK1A1, CSNK1G1 | SMN1; SMN2 4413/4885NPC1 1925/4885RAB9A 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.